Melissa Fluehr
Clinical research coordinator, Behavioral Science Unit, Icahn School of Medicine at Mount Sinai, New York, NY.
Ms. Fluehr has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.Maxwell Luber
Clinical research coordinator, Behavioral Science Unit, Icahn School of Medicine at Mount Sinai, New York, NY.
Mr. Luber has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.Barbara Coffey, MD, MS
Director, National Tourette Center of Excellence, Icahn School of Medicine at Mount Sinai
Dr. Coffey has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Tourette’s disorder (TD), also known as Tourette syndrome, is a fascinating yet complex neurodevelopmental disorder that can be challenging to treat. Dr. Georges Gilles de la Tourette, a French neurologist who described the first nine cases in 1885, had it right when he described the “peculiar” symptoms as a syndrome, later reporting that “fears, phobias, and arithmomania” were part of the picture.
Erica Greenberg, MD
Assistant psychiatrist at Massachusetts General Hospital; Pediatric Neuropsychiatry and Immunology Program within the OCD and Related Disorders Program at Massachusetts General Hospital, Boston, MA
Dr. Greenberg has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Dr. Greenberg works in the obsessive compulsive disorder (OCD) and related disorders program, and I see both kids with tics and OCD or OCD-related disorders as well as those with symptoms consistent with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) or pediatric acute-onset neuropsychiatric syndrome (PANS). She typically sees two to three new patients a week who fit somewhere in the OCD, tic, or PANDAS spectrum.
The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 2 CME credits.
Glen Elliott, MD, PhD
Editor-in-chief, The Carlat Child Psychiatry ReportDr. Elliott has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Changes in diagnostic criteria not only affect the clinical and public perception of a disorder, but also its perceived prevalence. Such is the case with autism. The evolution of the autism diagnosis since it was introduced into the Diagnostic and Statistical Manual (DSM) in 1980 inarguably has altered its reported prevalence.
Fred Volkmar, MD
Professor of psychology at the Yale Child Study Center, New Haven, CT
Dr. Volkmar has disclosed that he is an editor for Springer Publishing. Dr. Elliott has reviewed this article and found no evidence of bias in this educational activity.
Clinicians used to say, “Oh, autism is very clear. It’s the one true disorder in child psychiatry.” Now we realize that there’s a spectrum, which makes some sense, especially from a broad evolutionary perspective: If these changes were totally maladaptive, they presumably would have been lost over time; instead, they’ve persisted. That suggests that, for some people, some other combinations of these genes must be somewhat or even quite adaptive.
Glen Elliott, MD, PhD
Editor-in-chief, The Carlat Child Psychiatry Report
In November 2016, the FDA announced that it was requiring two companies to withdraw their generic versions of Concerta (OROS methylphenidate) because of efficacy concerns. Such actions are quite unusual, and when they occur, they tend to shake doctors’ confidence in the generic drug system—which branded drug companies are often eager to encourage. But the Concerta case is hardly an indictment of generic drugs, or even of generic stimulants. Let’s dig a little deeper for some insight into the generic drug process.
Colleen Ryan, MDDr. Ryan has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Study Reviewed: Lenhard F et al. Therapist-guided, Internet-delivered cognitive-behavioral therapy for adolescents with obsessive-compulsive disorder: A randomized controlled trial. J Am Acad Child Adolesc Psychiatry 2017;56(1):10–19. doi:10.1016/j.jaac.2016.09.515